Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
12,127 GBX | -0.32% | -2.00% | +14.36% |
May. 16 | AstraZeneca's Sipavibart Prevents COVID-19 in Immunocompromised Patients in Phase 3 Trial | MT |
May. 16 | Global markets live: Cisco, EasyJet, Roche, Netflix, Amazon... |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.36% | 239B | |
+32.36% | 694B | |
+30.24% | 593B | |
-1.60% | 371B | |
+20.07% | 331B | |
+6.04% | 290B | |
+10.22% | 209B | |
-3.03% | 209B | |
+9.27% | 169B | |
+0.45% | 164B |
- Stock Market
- Equities
- AZN Stock
- News AstraZeneca PLC
- AstraZeneca Says Calquence Combination Improves Progression-Free Survival in Phase 3 Mantle Cell Lymphoma Trial